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Objective The aims of this study were to determine cost effectiveness of screening for Chlamydia trachomatis
in hospital-based antenatal and gynaecology clinics, and community-based family planning clinics.
Additionally, women’s views of screening were determined in the hospital-based clinics.
Design Cost effectiveness based on decision model. Model probabilities were generated for a hypotheti-
cal sample of 250 women in each age group in each setting, based on prevalence studies, published
data and expert opinion. A prospective observational study was used to generate data on prevalence and
acceptability.
Setting Antenatal, gynaecology and family planning clinics in Aberdeen, Edinburgh and Glasgow.
Sample Prevalence was estimated in 2817 women. Acceptability was determined in 484 women.
Methods An economic evaluation was performed using prevalence data from this and a previous study, and
using outcome data from the literature and observational work. Incremental cost effectiveness ratios were
estimated for each age group and clinical setting. Sensitivity analyses were performed to determine the
robustness of incremental cost effectiveness ratios to changes in the incidence of long term sequelae and
costs. The prevalence of infection was determined by nucleic acid amplification of urine samples or
endocervical swabs. Knowledge of C. trachomatis and women’s views of screening were determined using
structured questionnaires.
Main outcome measures Direct health service costs of screening, incidence and costs associated with adverse
sequelae, women’s views of screening and prevalence of infection.
Results The estimated cost of screening 250 women in each age group in each the four sample populations
(total population of 3750) is £49,367, while preventing 64 major sequelae. This represents a net cost of
£771.36 in preventing one major sequela. Selective screening of all women under 20 years and all patients
attending abortion clinics were shown to be the most cost effective strategies. These results were relatively
insensitive to changes in estimated parameters, such as uptake rate, probabilities and unit costs of all major
sequlae averted. Prevalence (95% CI) of infection in the highest risk groups (those aged under 20 in both
antenatal and abortion clinics) was 12.1% (8.6–16.7) and 12.7% (7.3–21.2), respectively. The majority
(>95%) of women agreed with a policy of regular screening for C. trachomatis, and screening in the settings
employed in this study was largely acceptable.
Conclusions A single episode of screening for C. trachomatis does not result in net cost savings. Currently
recommended strategies of screening for C. trachomatis in women under 25 years of age in abortion clinics
are supported by our data on prevalence and acceptability. These data also suggest that hospital-based
screening strategies should be further extended to include younger women attending antenatal clinics and all
women of reproductive age attending colposcopy clinics.
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INTRODUCTION
Chlamydia trachomatis is the most common bacterial
sexually transmitted disease in the developed world and is
now a major public health problem.1 The annual UK health
service costs of treating the complications of C. trachomatis
are estimated to be greater than £100 million. Screening
and appropriate treatment of C. trachomatis in asympto-
matic women has been shown significantly to reduce the
risk of developing pelvic inflammatory disease.2,3 A strat-
egy of screening asymptomatic women has been suggested
by the Chief Medical Officer’s Expert Advisory Group
(UK), the Scottish Intercollegiate Guideline Network (Scot-
land), the Centers for Disease Control (USA) and the Cana-
dian Task Force on Periodic Health Examination.4 – 7 Each
of these protocols aims to target those most at risk of as-
cending infection.
Cost effectiveness analyses of opportunistic screening of
patients attending healthcare clinics, or specific high risk
groups, have been shown to be cost effective at prevalences
between 2% and 6%.8 – 10 Evidence from the current liter-
ature suggested that there are only a few situations where
screening would not be cost effective. However, the eco-
nomic impact of selective screening of different age groups
and risk factors is still unclear. There is a lack of detailed
information on the prevalence of C. trachomatis, particu-
larly in low risk asymptomatic women attending clinics in
hospital-based settings, on which to analyse cost effective-
ness. Additionally, the acceptability of screening for
C. trachomatis (crucial for an effective screening pro-
gramme) has not been studied in detail.11,12 The purpose
of this study was to model the cost effectiveness of
screening women in different age groups and healthcare
settings compared with no screening, from the perspective
of the National Health Service (NHS) in Scotland. We also
sought to add to the information required to deliver an
effective and efficient screening programme in antenatal
and gynaecology clinics by determining prevalence of
C. trachomatis using nucleic amplification techniques in
three settings where screening has been recommended:
antenatal, colposcopy and abortion clinics. Additionally,
we determined women’s knowledge and views of screening
for C. trachomatis.
METHODS
Women were recruited from those attending antenatal,
colposcopy and abortion clinics at each of Aberdeen Royal
Infirmary and Glasgow Royal Infirmary/Glasgow Royal
Maternity/Princess Royal Maternity Hospitals between
February 2001 and July 2002. Subjects were recruited into
four age cohorts: up to 20 years, 20–24 years, 25–29 years
and 30 years and above. The study was approved by each of
the local research ethics committees. All subjects saw a
researcher or midwife to discuss the study and gave
written informed consent to their inclusion in all parts of
the study.
Women were asked either to provide a first-void urine
sample (women attending antenatal clinics in each of
Glasgow and Aberdeen, and women attending abortion
clinics in Glasgow) or to allow an endocervical swab to
be taken (women attending colposcopy clinics in each of
Glasgow and Aberdeen, and women attending the abor-
tion clinic in Aberdeen). Urine samples were obtained at
the booking antenatal visit or on admission for abortion.
The endocervical swabs were taken at the time of colpo-
scopy or at the abortion clinic. All samples in Glasgow
were analysed using the LCx detection kit (Abbot Labora-
tories, Illinois, USA) according to the manufacturer’s in-
structions. In Aberdeen, the samples were analysed using
the BDProbeTec system (Becton Dickinson, Oxford, UK).
Positive results were confirmed by repeat testing of the
original sample.
The presence of symptoms or signs of C. trachomatis
infection was explored systematically and recorded.
A subsample of women attending the study antenatal and
colposcopy clinics who gave informed consent to the study
were sent the acceptability questionnaire by post with a
stamped address envelope. The questionnaire asked about
women’s knowledge of C. trachomatis, and their views on
screening. Non-response was addressed with one further
approach. Women attending abortion clinics were asked to
complete the questionnaire on site following written con-
sent. Sampling was opportunistic, and directed at recent
attendees once the questionnaire had been developed.
An incremental cost effectiveness analysis based on a
decision analytical model was performed. A decision ana-
lytical model was constructed to analyse a series of possible
events associated with screening and not screening for
C. trachomatis (Fig. 1). Major sequelae were defined as
pelvic inflammatory disease, chronic pelvic pain, ectopic
pregnancy, infertility, male urethritis, epididymitis, infan-
tile conjunctivitis and infantile pneumonia. The respective
baseline probabilities used in the model were based on data,
generated both from the analysis of the cohort and from
published literature (Table 1). The probabilities of devel-
oping individual sequelae and time to event were taken
from the literature. The clinical management strategy and
healthcare resource utilisation associated with all major
sequelae were obtained from literature and discussions with
the clinicians involved in the study (JN, SM). The effec-
tiveness of screening was measured by the number of major
sequelae averted.
Only direct health service costs were analysed. The costs
associated with screening and treating associated adverse
sequelae were calculated (Table 1). Because the numbers
sampled in each age and clinic group reflected the sampling
strategy, rather than the actual numbers attending these
clinics in the population, costs have been calculated for a
notional population of 1000 of each of antenatal, abortion
and family planning clinic attenders (250 patients in each
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age group in each clinic) and 750 colposcopy clinic attend-
ers (250 women in each age group, with women aged under
20 excluded since, as routine cervical screening does not
start until the age of 20 years, women under 20 years do not
commonly attend). The costs of screening included the
costs associated with patient recruitment, test samples
preparation, purchase of the diagnostic tests, follow up of
test positive patients and drug treatments for those infected.
The costs associated with managing adverse sequelae
included costs of all clinical investigations, hospitalisa-
tions, general practitioner (GP) consultations and drug
treatments.
Unit costs for all resources used were obtained from
routine collected data and the literature (Table 1) by expert
opinions, to obtain a net cost per patient associated with
various major sequelae. Future costs and benefits were
discounted at 5% and 3%, respectively, in accordance with
Treasury and Department of Health guidelines. All costs
were calculated at 2001 values (UK £).
Cost effectiveness is measured as a ratio of cost to
effectiveness. An incremental cost effectiveness ratio is
an estimate of the cost per unit of effectiveness of one
strategy in preference to another. In this study, incremental
cost effectiveness ratios presented as net costs per major
sequela averted, comparing screening with no screening,
were calculated for each individual age group and health-
care setting. Incremental cost effectiveness ratios are cal-
culated by dividing the difference in cost (in this case, costs
associated with screening and the costs of treating the
major adverse sequelae that the particular strategy failed
to prevent) by the difference in effectiveness (the number
Fig. 1. Decision tree for the screening of C. trachomatis.
Table 1. Estimated parameters—probabilities and costs.




Test positive patient follow upy 6
Antibiotic treatment 9
Uptake by index patients 91
Partner uptake 55
Cure rate 95
Partner transmission rate 68
Female sequelae
Pelvic inflammatory disease (PID) 302 190
a. Symptomatic PID 4025
b. Asymptomatic PID 6025
Chronic pelvic pain 1826 111








Cumulative risk of sequlae 128
Pregnancy rate 5
* Cost of testing and nurse time associated with sample collection
included.
y Cost of 30 minutes nurse time.
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of major sequelae prevented by the particular strategy) in
the comparison groups.
For the purpose of modelling, several key assumptions
were made. It was assumed that 10 minutes of nurse time13
was required for collecting and preparing screening samples
and 30 minutes of nurse time to follow up test positive pa-
tients for treatment. A single dose of azithromycin was used
in the basecase for treating test positive patients, and drug-
induced adverse events were assumed to be negligible.
Prevalence data were entered onto a Microsoft Access
Database, and analysed using SPSS. The m2 test was used
within each clinic type to compare prevalences across the
age cohorts. Logistic regression, with a positive test for
C. trachomatis as the dependent variable, was used to
explore variables which might be associated with an in-
creased or decreased risk of C. trachomatis infection (age,
clinic type, geographical region, Carstairs score,14 symp-
toms of infection, signs of infection, having had a test for
C. trachomatis within the previous six months, having a
previous pregnancy, or [among pregnant women only]
bleeding). The odds ratios (95% confidence intervals [CI])
associated with these variables were calculated. Variables
which appeared significant when entered into a logistic
regression model singly were then entered into a multiple
logistic regression model to give adjusted odds ratios. The
goodness of fit of the final model was tested by the method of
Hosmer and Lemeshow.15 The acceptability data were
analysed using SPSS, with the m2 test used to explore
differences between groups.
RESULTS
A total of 3132 women (1598 women in Aberdeen and
1534 women in Glasgow) were approached about the study.
Only 49 (1.6%) declined to participate. Four women were
ineligible, 255 (8.1%) were excluded for a variety of
reasons, and a further 7 (0.2%) had unusable results,
leaving a final sample size of 2817 (90% of those ap-
proached). Recruitment in the under 20 age group in colpo-
scopy was abandoned within a few months of the start of
the study, after it became clear there would be insufficient
women in this group for analysis to be meaningful. Those
women already recruited to this group were excluded from
subsequent analysis.
The prevalence of infection by age group is shown in
Table 2. The highest reported prevalence was in the under
20 age group, where the prevalence (95% CI) in women
attending for abortion was 12.6% (8.5–18.3%) and 12.1%
(8.6–16.7%) in women attending for antenatal care. There
was a significant decline in prevalence with increasing age
in both antenatal and abortion clinics, but not in colposcopy
clinics.
When potential risk factors for a positive result were
analysed individually, each of age, clinic source, geograph-
ical region (Aberdeen or Glasgow) and Carstairs score
appeared important (Table 3). However, in a multiple lo-
gistic regression model, only age, clinic type and geograph-
ical region of origin were significant (Table 3). Similar
results were obtained whether Carstairs score was grouped
into three categories prior to analysis (high [6 and 7],
medium [3, 4 and 5] and low [1 and 2]), or analysed as
seven ordered categories. Although none of the pa-
tients in the antenatal clinic had signs or symptoms of
C. trachomatis which prompted testing by the primary
clinician, on further questioning 9% had symptoms which
could be attributable to C. trachomatis infection. Among
the colposcopy and abortion clinics, 13% of women had
symptoms or signs possibly attributable to infection with
C. trachomatis. There was no difference in prevalence of
C. trachomatis between those who did and those who did
not have symptoms or signs potentially attributable to infec-
tion. Additionally, neither having a test for C. trachomatis
Table 2. Percentage prevalence (95% CI) of C. trachomatis in each clinic










12.1% (8.6– 16.7) 12.6% (8.5– 18.3)
20– 24 18/404 14/158 24/211
4.4% (2.8– 6.9) 8.9% (5.2– 14.5) 11.4% (7.7– 16.5)
25– 29 6/435 6/152 5/171
1.4% (0.6– 3.1) 3.9% (1.7– 8.6) 2.9% (1.1– 6.9)
30 3/434 9/203 6/206
0.7% (0.1– 2.1) 4.4% (2.3– 8.4) 2.9% (0.6– 5.1)
P < 0.001 P ¼ 0.42 P < 0.01
Table 3. Odds ratio of a positive test for C. trachomatis for the variables
age, clinic attended, region and Carstairs score. The unadjusted results
were obtained by use of each of the variables alone in a logistic regression
process. The adjusted results were obtained by a backwards elimination.
Carstairs score was not a significant factor in this model and the final model
therefore included the variables age, clinic attended and region alone.
Goodness of fit was confirmed by the method of Hosmer and Lemeshow.
Variable Unadjusted Adjusted
Odds ratio (95% CI) P Odds ratio (95% CI) P
Age* 0.881 (0.852– 0.911) <0.001 0.878 (0.846–0.912) <0.001
Clinic attendedy
Abortion 2.07 (1.42– 3.01) <0.001 2.22 (1.23–3.99) 0.008
Colposcopy 1.61 (1.03– 2.52) 0.036 1.75 (1.16–2.65) 0.008
Regionz 1.81 (1.28– 2.55) <0.001 1.65 (1.07–2.54) 0.023
Carstairs score§
Each of 2 –6 ns
7 2.93 (1.23– 6.92) 0.014
* Odds ratio for every one year’s increase in age.
y Compared with antenatal clinic as reference.
z Glasgow compared with Aberdeen as reference.
§ Compared with Carstairs 1 as reference.
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within the past six months, having a previous pregnancy, nor
(among pregnant women only) bleeding were associated
with an increased risk of a positive result (data not shown).
Five hundred and twenty one women responded to the
acceptability questionnaire (77% response rate). Thirty-
seven were 50 years or more and were omitted from
subsequent analyses. Within each clinic, respondents were
evenly distributed among the four (antenatal or abortion) or
three (colposcopy) age groups (data not shown), and were
similar in other characteristics to the main sample.
Four hundred and five women (84%) thought that the
clinic in which they were tested was the appropriate one to
be tested, while 375 women (78%) thought that the timing
of the test was appropriate (see Table 4). There was
significant variation of viewpoint by respective clinic;
women from the antenatal clinic were least likely to think
that their clinic was the suitable place, although the re-
sponse was still very positive. Responses were also positive
to the suggestion that C. trachomatis screening could take
place at the same time as a cervical smear test (89%).
Most women thought that men should be tested routinely
(93%). A smaller number thought that they would want
their partner to be tested (77%). Fewer thought that their
partner would attend (46%).
The majority of women (93%) said that they had heard
of C. trachomatis, successfully identified the definition of
C. trachomatis from a list (99%) and identified that it
could be caught through sexual intercourse (97%). Women
who ‘didn’t know’ if they had ever been tested were
significantly less likely to know how C. trachomatis
could be caught (P < 0.001). Fewer women knew that
C. trachomatis could be caught more than once (63%), with
women who had been screened before more likely to
respond correctly (P < 0.01). The majority correctly
identified that neither women nor men would always know
if they had C. trachomatis (86%, women would not always
know and 73%, men), those who had been previously tested
were significantly more likely to be correct.
Based on prevalences found in this and a previous
study,13 in the absence of screening 217 women out of this
notional population of 3500 (6.2%) would be positive for
C. trachomatis (Table 3) at a cost of £7806. A universal
screening strategy, providing tests for the complete study
cohort, would prevent 64 cases of major adverse sequelae
at a cost of £49,367. This produced an incremental cost
effectiveness ratio of £651, representing net cost per major
sequelae averted.
Selective age-based screening was more cost effective
than universal screening. The results of the analysis showed
the younger the age group screened, the more cost effective
the screening strategy. The incremental cost effectiveness
ratios for selective screening of women under 20 years,
under 25 years and under 30 years were £258, £344 and
£513, respectively.
Selective screening by clinical setting was also shown to
be less cost effective than universal screening, with the
exception of colposcopy and abortion clinics (incremental
cost effectiveness ratios ¼ £621 and £433, respectively).
Table 5. Prevalence, costs, sequelae averted, incremental cost effective-
ness ratios by age and settings. Assuming population of 250 in each age











Universal screening 6.2 64 49,367 651
Selective screening by age
Under 20 years 11 30 15,122 258
Under 25 years 7.9 54 25,988 344
Under 30 years 2.7 59 37,529 513
Selective screening by clinical setting
Family planning
clinic
5 16 18,919 694
Antenatal clinic 5 9 19,107 1196
Colposcopy clinic 6 25 16,105 621
Abortion clinic 8 13 18,655 433












Yes 71 84 81 0.004
No 17 5 9
Don’t know 12 11 10
Appropriate
clinic?
Yes 77 92 83 0.001
No 16 3 3
Don’t know 7 5 5
Table 6. Sensitivity analysis—impact of varying model input variables on











50% 20% þ20% 50% þ50%
Universal screening £651 £651 £857 £514 £325 £978
Selective screening by age
Under 20 years £258 £257 £352 £195 £128 £388
Under 25 years £344 £343 £462 £264 £171 £517
Under 30 years £513 £512 £679 £401 £255 £770
Selective screening by clinical setting
Family planning
clinic
£694 £694 £912 £549 £346 £1043
Antenatal clinic £1196 £1195 £1560 £953 £597 £1796
Colposcopy
clinic
£621 £621 £818 £490 £310 £934
Abortion clinic £433 £433 £577 £337 £216 £651
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This latter option was the most cost effective selective
screening strategy by clinical setting.
Other selective screening scenarios on various age
groups and clinical settings were also investigated. Selec-
tive screening of under 20 years was the most cost effective
screening strategy irrespective of clinical settings (Table 5).
One-way univariate sensitivity analysis showed that the
results of the model are relatively robust (Table 6). When
varying estimates of screening uptake rate, the incremental
cost effectiveness ratios of the basecase remained stable
and the results of the model remained unchanged.
DISCUSSION
Asymptomatic carriage of C. trachomatis fulfils the
Wilson and Junger criteria for a condition where screening
is appropriate, and many expert groups now believe the
case for screening for C. trachomatis has been made.16 For
a screening programme to be effective, it should be targeted
at (sub)populations where the prevalence is highest, where
screening is acceptable (and the uptake likely to be high)
and where the additional costs of screening versus not
screening are likely to be least. In this study, we determined
the cost effectiveness, the prevalence and the acceptability
of screening in a variety of hospital-based clinic settings,
and these data will inform appropriate screening strategies.
Compared with no screening, selective screening of the
most prevalent patient population was the most cost effec-
tive strategy, namely, screening abortion patients (the most
prevalent healthcare setting) and patients under 20 years
(the most prevalent age group).
In contrast to current literature, we did not find screening
for C. trachomatis to be cost saving. These studies dem-
onstrated cost savings with screening in population with
prevalence between 3% and 10%.17 However, the results
from these models tend to be country specific and are not
transferable to the general UK healthcare setting. This study
was based on prevalence and resource data from a UK
setting. The results showed that, based on universal screen-
ing, it would cost approximately £771 to prevent one major
sequela. In addition, this model has taken into account the
acceptability of screening by incorporating the rate of up-
take. This is a particularly important factor in screening
programmes. Although the acceptability rate recorded in this
cohort was unusually high, sensitivity analysis has shown
that the results were insensitive to varying uptake rate.
The Chief Medical Officer’s expert advisory group rec-
ommended that everyone with symptoms of chlamydial in-
fection, all those attending genitourinary medicine clinics
and those seeking abortion should be targeted for screening.5
Opportunistic screening of sexually active women under
25 years and those over 25 with a new sexual partner or
two or more sexual partners in the previous year was
also encouraged. The findings of this study have gener-
ally supported these recommendations from an economic
perspective. Selective screening has clear clinical and eco-
nomic benefit compared with no screening and universal
screening.
This study has potential limitations that are inherent to
all cost effectiveness analysis. Based on a decision anal-
ysis, this study used estimates from several sources such as
probabilities of clinical events reported in the medical
literature and expert opinion on management of events. In
an attempt to overcome the potential bias, all estimates
were varied in the sensitivity analysis to determine the
effect that variations would have on the results. The results
of the sensitivity analysis showed that the results are
relatively robust.
This model has been designed to investigate the most
cost effective strategy for C. trachomatis screening, based
on the assumption that a decision has been made to un-
dertake screening and does not consider the relative cost
effectiveness of screening compared with other uses of
scarce NHS resources. To determine the relative value
of a Chlamydia screening program to other healthcare
programmes, a cost–benefit analysis is required in these
settings.
We found that the prevalence of infection in young
women attending for antenatal care was high—12.1%
(95% CI 8.6–16.7%) in women under 20 years of age and
4.4% (2.8–6.9%) in women between 20 and 24 years of
age. These prevalences are similar to those found in other
studies of hospital-based antenatal patients.18 – 20 Together,
these data support a strategy of screening women under
25 years of age for C. trachomatis in hospital- or community-
based antenatal clinics. Although widely recommended,
such a strategy is not commonly adopted. This is perhaps
surprising, since C. trachomatis in pregnancy is associated
with additional complications including preterm delivery21
(odds ratio [95% CI] of 2.2 [2.2–9.57] in association with
C. trachomatis carriage at 24 weeks) and neonatal conjunc-
tivitis and pneumonia. Additionally, the economic evalua-
tion suggested that screening was only marginally less cost
effective in this setting than in abortion clinics. We suggest
that those caring for pregnant women should consider
whether screening strategies should be introduced among
their own patients.
In contrast to antenatal clinics, screening in abortion
clinics is well established in the UK. The prevalences in the
under 20 year and the 20–24 age group in abortion clinics
in our study are similar to other recent UK data.19,22 Fewer
published data exist on the prevalence of C. trachomatis in
women attending colposcopy. Overall prevalences of
C. trachomatis of 3.0–7.9%19,23,24 have been reported
among otherwise unselected women attending colposcopy
clinics, but these data were not further analysed by age.
Notwithstanding, the prevalence in our study in women of
25 years and older (>4%), and the finding in this small
sample that this figure does not decline with age, suggests
that screening strategies in this setting should include older
women.
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Very few studies indeed have examined the acceptability
by women (or men) of such routine screening.7,8,12 Before
undertaking the study, we hypothesised that screening
might be more acceptable in the antenatal setting than
elsewhere, as screening is routinely undertaken for a
variety of other infective conditions in pregnancy (e.g.
syphilis and rubella). We found that in all three settings
there was a high level of acceptability of the test, although
fewer antenatal patients than those attending other clinics
responded positively to this question. The suggestion that
men might not respond so positively is worth exploring in
more detail; there are too few studies at present with which
to compare our findings.
The study demonstrated a high level of first level knowl-
edge about C. trachomatis although with the increasing
sophistication of the questions the knowledge level dropped
substantially. This knowledge will include information ac-
quired during the process of informed consent as that patient
was recruited into the study. The small group of women
who had been previously tested had a much higher level of
knowledge about the condition suggesting, not surprisingly,
that experience with the condition increased knowledge.
SUMMARY
A single episode of screening for C. trachomatis does
not result in net cost savings. Currently recommended
strategies of screening for C. trachomatis in women under
25 years of age in abortion clinics are supported by our data
on prevalence and acceptability. These data also suggest
that hospital-based screening strategies should be further
extended to include younger women attending antenatal
clinics and all women of reproductive age attending colpo-
scopy clinics.
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